Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.

Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, Mankin H, Duan Z.

Cancer Chemother Pharmacol. 2011 Feb;67(2):439-46. doi: 10.1007/s00280-010-1344-7. Epub 2010 May 12.

PMID:
20461381
2.

Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.

Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, Mankin H, Duan Z.

Anticancer Res. 2011 Apr;31(4):1115-23.

3.

Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.

Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC.

Clin Cancer Res. 2009 May 15;15(10):3472-83. doi: 10.1158/1078-0432.CCR-08-2714. Epub 2009 May 5. Erratum in: Clin Cancer Res. 2015 Apr 1;21(7):1774-5.

4.

Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.

Heinicke U, Fulda S.

Cancer Lett. 2014 Aug 28;351(1):50-8. doi: 10.1016/j.canlet.2014.04.021. Epub 2014 May 6.

PMID:
24814395
5.

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.

Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR.

Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21.

PMID:
20650529
6.

RuvBL2 is involved in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells.

Zhan Q, Tsai S, Lu Y, Wang C, Kwan Y, Ngai S.

PLoS One. 2013 Aug 16;8(8):e71663. doi: 10.1371/journal.pone.0071663. eCollection 2013.

7.

Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.

Blanquart C, François M, Charrier C, Bertrand P, Gregoire M.

Curr Cancer Drug Targets. 2011 Oct;11(8):919-28.

PMID:
21762083
8.

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.

Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC.

BMC Cancer. 2017 Jan 21;17(1):67. doi: 10.1186/s12885-017-3046-6.

9.

Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.

Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMullan C, Miller JW, Marks PA, Mitsiades N.

Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4072-9. doi: 10.1167/iovs.09-3517. Epub 2009 Apr 22.

PMID:
19387079
10.

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.

Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7. Epub 2007 Nov 27.

11.

CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.

Kim HM, Kim CS, Lee JH, Jang SJ, Hwang JJ, Ro S, Hyun YL, Choi J.

Breast Cancer Res Treat. 2011 Nov;130(2):365-75. doi: 10.1007/s10549-010-1310-4. Epub 2010 Dec 24.

PMID:
21184271
13.

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.

Cheriyath V, Kuhns MA, Kalaycio ME, Borden EC.

Br J Cancer. 2011 Mar 15;104(6):957-67. doi: 10.1038/bjc.2011.42. Epub 2011 Mar 1.

14.
15.

Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.

Sonnemann J, Trommer N, Becker S, Wittig S, Grauel D, Palani CD, Beck JF.

Cancer Biol Ther. 2012 Apr;13(6):417-24. doi: 10.4161/cbt.19293. Epub 2012 Apr 1.

PMID:
22313685
16.

Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis.

Wetzel M, Premkumar DR, Arnold B, Pollack IF.

J Neurosurg. 2005 Dec;103(6 Suppl):549-56.

PMID:
16383255
17.

A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.

Hwang JJ, Kim YS, Kim MJ, Jang S, Lee JH, Choi J, Ro S, Hyun YL, Lee JS, Kim CS.

Anticancer Drugs. 2009 Oct;20(9):815-21. doi: 10.1097/CAD.0b013e3283300a0f.

PMID:
19644355
18.

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.

Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, Dolo V, Tombolini V, Jannini EA, Festuccia C.

Int J Oncol. 2012 Mar;40(3):711-20. doi: 10.3892/ijo.2011.1270. Epub 2011 Nov 23.

PMID:
22134754
19.

The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.

Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P.

Br J Haematol. 2010 May;149(4):518-28. doi: 10.1111/j.1365-2141.2010.08124.x. Epub 2010 Mar 1.

PMID:
20201941
20.

Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.

Xargay-Torrent S, López-Guerra M, Saborit-Villarroya I, Rosich L, Campo E, Roué G, Colomer D.

Clin Cancer Res. 2011 Jun 15;17(12):3956-68. doi: 10.1158/1078-0432.CCR-10-3412. Epub 2011 Jun 7.

Supplemental Content

Support Center